Pfenex names FDA's John Taylor to board
This article was originally published in Scrip
Pfenex, a clinical-stage biotechnology company developing biosimilar therapeutics and difficult to manufacture proteins, has appointed John Taylor to its board of directors. Mr Taylor joins Pfenex's board after a distinguished career with the US FDA, most recently in the position of counselor to the commissioner, and previously acting deputy principal commissioner and deputy commissioner for global regulatory operations and policy. Currently Mr Taylor is a principal at Greenleaf Health, a full-service consulting firm that provides strategic guidance to FDA-regulated companies that are developing innovative solutions to pressing public health challenges.